TECH · Bio-Techne Corp
$71.60
+0.63% last session
End-of-day data · updated 2026-07-28
Market cap
$11B
Enterprise value
$11B
Trailing P/E
102.3
Forward P/E
35.0
Dividend yield
0.0%
Beta
1.29
Avg volume
5M
Employees
3K
2D change
—
5D change
-0.21%
10D change
-0.69%
30D change
0.87%
60D change
38.58%
MTD change
0.87%
YTD change
22.17%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TECH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-09
Latest call per bank · past 12 months
RBC Capital
Sector Perform$73.00
+2.0% vs priceCitigroup
Neutral$73.00
+2.0% vs priceWells Fargo
Overweight$62.00
-13.4% vs priceUBS
Buy$79.00
+10.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | RBC Capital | Downgrade | Outperform → Sector Perform | $62.00 → $73.00 |
| 2026-06-30 | TD Cowen | Downgrade | Buy → Hold | $65.00 → $73.00 |
| 2026-06-30 | Benchmark | Downgrade | Buy → Hold | $0.00 |
| 2026-06-29 | Citigroup | Downgrade | Buy → Neutral | $70.00 → $73.00 |
| 2026-06-26 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $68.00 → $73.00 |
| 2026-06-26 | William Blair | Downgrade | Outperform → Market Perform | $0.00 |
| 2026-06-26 | Baird | Maintains | Neutral | $49.00 → $73.00 |
| 2026-06-11 | Piper Sandler | Initiates | Neutral | $0.00 → $65.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 75 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 19.8% above the 50-day MA ($60.14).
- Price vs 200-day MA: Trading 21.6% above the 200-day MA ($59.26).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.64) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($72.12).
TECH Price Chart
Loading chart for TECH…
Fundamentals
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.